8-K: PDS Biotech Announces Positive Data for Versamune HPV in Head and Neck Cancer Trials

PDS Biotechnology announces positive extended follow-up data for VERSATILE-002 and additional trials evaluating Versamune HPV to be presented at the 2025 ASCO Annual Meeting.

Summary

• PDS Biotechnology has announced the publication of three Versamune HPV abstracts to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
• The abstracts summarize studies of Versamune HPV (PDS0101) in head and neck cancer.
• VERSATILE-002 Phase 2 trial showed a median overall survival (mOS) of 39.3 months in patients with CPS ≥ 20 when treated with Versamune HPV and pembrolizumab.
• VERSATILE-002 Phase 2 trial showed a median overall survival (mOS) of 30.0 months in patients with CPS ≥ 1 when treated with Versamune HPV and pembrolizumab.
• The ongoing VERSATILE-003 Phase 3 trial is evaluating Versamune HPV with pembrolizumab as a first-line treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).
• A Phase 2 trial (MC200710) investigating Versamune HPV alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal carcinoma showed clinical activity.
• 70% of patients who received Versamune HPV alone had stable disease.
• 100% of patients who received Versamune HPV with pembrolizumab had stable disease or partial response.
• The combination of Versamune HPV and pembrolizumab met the trial's primary endpoint of a 50% reduction in circulating tumor DNA (ctDNA) response.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, particularly the extended survival rates observed in the VERSATILE-002 trial. This suggests a promising outlook for the company's lead product candidate and its potential impact on treating head and neck cancer.

Positives

• The VERSATILE-002 data shows the longest survival reported to date in first-line recurrent/metastatic head and neck cancer.
• The VERSATILE-003 trial is the only registrational trial for the rapidly growing population of patients with HPV16-positive recurrent/metastatic HNSCC.
• The Phase 2 trial (MC200710) showed promising clinical activity with Versamune HPV alone or in combination with pembrolizumab.
• The combination of Versamune HPV and pembrolizumab met the trial's primary endpoint of a 50% reduction in circulating tumor DNA (ctDNA) response in the MC200710 trial.

Risks

• The company's future performance depends on the success of its clinical trials and the commercialization of its product candidates.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• The company's limited operating history makes it difficult to evaluate its prospects.

Future Outlook

The company is focused on advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers and developing Versamune HPV in combination with other therapies.

Management Comments

• Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech stated, 'We continue to be excited about the strength and durability of the VERSATILE-002 data showing the longest survival reported to date in 1L recurrent/metastatic (r/m) head and neck cancer (HNSCC).'
• Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech stated, 'These results further strengthen our confidence in the ongoing VERSATILE-003 trial, which is the only registrational trial for the rapidly growing population of patients with HPV16-positive r/m HNSCC.'

Industry Context

The announcement highlights the growing importance of immunotherapy in treating HPV16-positive head and neck cancers. The results from the VERSATILE-002 trial, showing extended survival, could position Versamune HPV as a significant player in this therapeutic area.

Comparison to Industry Standards

• The median overall survival (mOS) of 39.3 months in patients with CPS ≥ 20 in the VERSATILE-002 trial is significantly higher than the published mOS for pembrolizumab alone, which is approximately 15 months.
• The median overall survival (mOS) of 30.0 months in patients with CPS ≥ 1 in the VERSATILE-002 trial is significantly higher than the published mOS for pembrolizumab alone, which is approximately 12 months.
• These results suggest that the combination of Versamune HPV and pembrolizumab may offer a significant improvement in survival compared to pembrolizumab alone in HPV16-positive recurrent/metastatic HNSCC.

Stakeholder Impact

• Positive results could lead to improved treatment options and outcomes for patients with HPV16-positive head and neck cancer.
• Successful clinical trials and potential commercialization of Versamune HPV could benefit shareholders.
• Positive data may enhance the company's reputation and attract potential partners or investors.

Next Steps

• Presentation of Versamune HPV study abstracts at the 2025 ASCO Annual Meeting.
• Continued enrollment in the VERSATILE-003 Phase 3 trial.
• Interim readouts planned for the VERSATILE-003 Phase 3 trial.

Key Dates

Keywords

Versamune HPV, PDS0101, PDS Biotechnology, Head and Neck Cancer, HNSCC, Pembrolizumab, Immunotherapy, ASCO, Clinical Trial, HPV16-positive